Nasdaq confirms Eargo’s minimum bid price deficiency ‘cured’

Eargo announced that it received a letter from The Nasdaq Stock Market dated February 1 informing Eargo that the Company’s minimum bid price deficiency has been cured. The letter from Nasdaq follows the Company’s 1-for-20 reverse stock split approved by stockholders on October 12.